Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) – By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, Mexico, France, Germany, Italy, Spain, China, India, Japan)
EXECUTIVE SUMMARY
Global Overactive Bladder Treatment Market was valued at USD 4978.09 Million in the year 2018. New emerging technologies and drug development with expanding health expenditure and infrastructure, rising number of elderly people etc. is driving the Overactive Bladder Treatment market. Further, advent of combination therapy, rising drug approval will bolster the overactive bladder treatment market. In addition, the ongoing developments and advancements of treatments in pharmaceutical industry will create the demand for high-efficient Overactive Bladder Treatment that are likely to boost the growth of Overactive Bladder Treatment market across all over the globe.
By Medication, Oxybutynin has been estimated to propel the market growth globally mainly owing to its cost effectiveness, good efficiency and lower rate of adherence in OAB treatment. By Therapy, BOTOX Treatment will have high growth rate, due to the fact that BOTOX is more cost-effective, even when performed in the hospital under general anesthesia. However, it can also be performed under local anesthesia. Furthermore, Botox is one-step procedure and does not require the implantation of a foreign body. BOTOX Therapy is an acceptable treatment for physicians as well and requires fewer extra skills beyond those necessary for a cystoscopic. Botox is safe, with the only side effect being the temporary need to catheterize in 6% of cases and UTI in 18% of cases.
Based on Therapy, SNM Therapy is expected to propel and have higher growth rate owing to its significantly higher completely dry rates and higher zero pad usage, improvement in frequency/urgency, and causes no change in voiding efficiency. Further, SNM therapy is more holistic than BOTOX Therapy and is a restorative therapy and returns function back to the patient. SNM does carry more complications (about 20%), mostly comprising undesirable stimulation and pain at the implant site.
SCOPE OF THE REPORT
Global Overactive Bladder Treatment Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Global Overactive Bladder Treatment Market was valued at USD 4978.09 Million in the year 2018. New emerging technologies and drug development with expanding health expenditure and infrastructure, rising number of elderly people etc. is driving the Overactive Bladder Treatment market. Further, advent of combination therapy, rising drug approval will bolster the overactive bladder treatment market. In addition, the ongoing developments and advancements of treatments in pharmaceutical industry will create the demand for high-efficient Overactive Bladder Treatment that are likely to boost the growth of Overactive Bladder Treatment market across all over the globe.
By Medication, Oxybutynin has been estimated to propel the market growth globally mainly owing to its cost effectiveness, good efficiency and lower rate of adherence in OAB treatment. By Therapy, BOTOX Treatment will have high growth rate, due to the fact that BOTOX is more cost-effective, even when performed in the hospital under general anesthesia. However, it can also be performed under local anesthesia. Furthermore, Botox is one-step procedure and does not require the implantation of a foreign body. BOTOX Therapy is an acceptable treatment for physicians as well and requires fewer extra skills beyond those necessary for a cystoscopic. Botox is safe, with the only side effect being the temporary need to catheterize in 6% of cases and UTI in 18% of cases.
Based on Therapy, SNM Therapy is expected to propel and have higher growth rate owing to its significantly higher completely dry rates and higher zero pad usage, improvement in frequency/urgency, and causes no change in voiding efficiency. Further, SNM therapy is more holistic than BOTOX Therapy and is a restorative therapy and returns function back to the patient. SNM does carry more complications (about 20%), mostly comprising undesirable stimulation and pain at the implant site.
SCOPE OF THE REPORT
Global Overactive Bladder Treatment Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)
- Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
- Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
- Analysis By Therapy: BOTOX, SNM Therapy, PTNS
- Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
- Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
- Analysis By Therapy: BOTOX, SNM Therapy, PTNS
- Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
- Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
- Analysis By Therapy: BOTOX, SNM Therapy, PTNS
- Pipeline Product Analysis
- Market Attractiveness Charts
- Competitive Landscape
- Leading Companies
- Market Dynamics – Drivers, Trends and Restraints
- Market Trends
- SWOT Analysis
- Porter’s Five Forces Analysis
- Company Analysis – Sanofi S.A., Macleod’s pharmaceuticals Ltd., Apotex, Axonics modulation technologies, Intas Pharmaceuticals, Teva Pharmaceuticals, Laborie, Pfizer Inc., Allergan, Astellas Pharma Inc.
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. REPORT SCOPE & METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Asia Pacific region to witness augmented growth in the forecast period.
2.2 Contribution in Research and Development activities to expand the overactive bladder treatment products.
3. GLOBAL OVERACTIVE BLADDER PRODUCT OUTLOOK
4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: AN ANALYSIS
4.1 Market Size, By Value, Year 2014-2024
5. GLOBAL OVERACTIVE BLADDER TREATMENT SEGMENTATION BY MEDICATION(BY VALUE)
5.1 Competitive Scenario of Global Overactive Bladder Treatment Market – By Medication
5.2 Oxybutynin – Market Size and Forecast (2014-2024)
5.3 Tolterodine – Market Size and Forecast (2014-2024)
5.4 Tropism – Market Size and Forecast (2014-2024)
5.5 Solifenacin – Market Size and Forecast (2014-2024)
5.6 Mirabegron – Market Size and Forecast (2014-2024)
5.7 Others – Market Size and Forecast (2014-2024)
6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION BY THERAPY(BY VALUE)
6.1 Competitive Scenario of Global Overactive bladder treatment: By Therapy
6.2 BOTOX– Market Size and Forecast (2014-2024)
6.3 SNM Therapy- Market Size and Forecast (2014-2024)
6.4 PTNS Therapy-Market Size and Forecast (2014-2024)
7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: REGIONAL ANALYSIS
7.1 Competitive Scenario of Global Overactive Bladder Treatment: By Region
8. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET: BY ANALYSIS
8.1 North America Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.2 Market Segmentation By Medication
8.3 Market Segmentation By Therapy
8.4 North America Global Overactive Bladder Treatment Market: Country Analysis
8.5 Market Opportunity Chart of North America Overactive Bladder treatment Market - By Country, By Value (Year-2024)
8.6 Competitive Scenario of North America Overactive Bladder treatment : By Country
8.7 United States Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.8 United States Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.9 Canada Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.10 Canada Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.11 Mexico Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.12 Mexico Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9. EUROPE OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
9.1 Europe Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.2 Market Segmentation By Medication
9.3 Market Segmentation By Therapy
9.4 Europe Global Overactive Bladder Treatment Market: Country Analysis
9.5 Market Opportunity Chart of Europe Overactive Bladder treatment Market - By Country, By Value (Year-2024)
9.6 Competitive Scenario of Europe Overactive Bladder treatment : By Country
9.7 France Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.8 France Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.9 Germany Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.10 Germany Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.11 Italy Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.12 Italy Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.13 Spain Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.14 Spain Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10. APAC OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
10.1 APAC Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.2 Market Segmentation By Medication
10.3 Market Segmentation By Therapy
10.4 APAC Global Overactive Bladder Treatment Market: Country Analysis
10.5 Market Opportunity Chart of APAC Overactive Bladder treatment Market - By Country, By Value (Year-2024)
10.6 Competitive Scenario of APAC Overactive Bladder treatment : By Country
10.7 India Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.8 India Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10.9 China Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.10 China Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10.11 Japan Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.12 Japan Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
11. ROW OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
11.1 ROW Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
11.2 Market Segmentation By Medication
11.3 Market Segmentation By Therapy
12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
12.1 Global Overactive Bladder Treatment Market Drivers
12.2 Global Overactive Bladder Treatment Market Restraints
12.3 Global Overactive Bladder Treatment Market Trends
13. MARKET ATTRACTIVENESS AND STRATEGIC ANALYSIS
13.1 Market Attractiveness
13.2 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year 2024)
13.3 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
13.4 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)
14. PIPELINE PRODUCT ANALYSIS
14.1 New Technologies in Overactive Bladder Treatments
14.2 Key Pipeline Drugs in Overactive Bladder Treatment Market
14.3 Key new operative therapies in Overactive Bladder Treatment Market
15. COMPETITIVE LANDSCAPE
15.1 Market Share Analysis
15.2 SWOT Analysis
15.3 Porter’s Five Force Analysis
16. COMPANY PROFILES (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
16.1 Astellas Pharma Inc.
16.2 Allergan
16.3 Pfizer Inc.
16.4 Laborie
16.5 Teva Pharmaceutical
16.6 Intas Pharmaceutical Ltd.
16.7 Axonics Modulation Technologies, Inc.
16.8 Apotex
16.9 Macleods Pharmaceuticals Ltd.
16.10 Sanofi S.A.
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Asia Pacific region to witness augmented growth in the forecast period.
2.2 Contribution in Research and Development activities to expand the overactive bladder treatment products.
3. GLOBAL OVERACTIVE BLADDER PRODUCT OUTLOOK
4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: AN ANALYSIS
4.1 Market Size, By Value, Year 2014-2024
5. GLOBAL OVERACTIVE BLADDER TREATMENT SEGMENTATION BY MEDICATION(BY VALUE)
5.1 Competitive Scenario of Global Overactive Bladder Treatment Market – By Medication
5.2 Oxybutynin – Market Size and Forecast (2014-2024)
5.3 Tolterodine – Market Size and Forecast (2014-2024)
5.4 Tropism – Market Size and Forecast (2014-2024)
5.5 Solifenacin – Market Size and Forecast (2014-2024)
5.6 Mirabegron – Market Size and Forecast (2014-2024)
5.7 Others – Market Size and Forecast (2014-2024)
6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION BY THERAPY(BY VALUE)
6.1 Competitive Scenario of Global Overactive bladder treatment: By Therapy
6.2 BOTOX– Market Size and Forecast (2014-2024)
6.3 SNM Therapy- Market Size and Forecast (2014-2024)
6.4 PTNS Therapy-Market Size and Forecast (2014-2024)
7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: REGIONAL ANALYSIS
7.1 Competitive Scenario of Global Overactive Bladder Treatment: By Region
8. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET: BY ANALYSIS
8.1 North America Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.2 Market Segmentation By Medication
8.3 Market Segmentation By Therapy
8.4 North America Global Overactive Bladder Treatment Market: Country Analysis
8.5 Market Opportunity Chart of North America Overactive Bladder treatment Market - By Country, By Value (Year-2024)
8.6 Competitive Scenario of North America Overactive Bladder treatment : By Country
8.7 United States Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.8 United States Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.9 Canada Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.10 Canada Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.11 Mexico Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.12 Mexico Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9. EUROPE OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
9.1 Europe Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.2 Market Segmentation By Medication
9.3 Market Segmentation By Therapy
9.4 Europe Global Overactive Bladder Treatment Market: Country Analysis
9.5 Market Opportunity Chart of Europe Overactive Bladder treatment Market - By Country, By Value (Year-2024)
9.6 Competitive Scenario of Europe Overactive Bladder treatment : By Country
9.7 France Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.8 France Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.9 Germany Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.10 Germany Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.11 Italy Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.12 Italy Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9.13 Spain Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
9.14 Spain Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10. APAC OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
10.1 APAC Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.2 Market Segmentation By Medication
10.3 Market Segmentation By Therapy
10.4 APAC Global Overactive Bladder Treatment Market: Country Analysis
10.5 Market Opportunity Chart of APAC Overactive Bladder treatment Market - By Country, By Value (Year-2024)
10.6 Competitive Scenario of APAC Overactive Bladder treatment : By Country
10.7 India Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.8 India Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10.9 China Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.10 China Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
10.11 Japan Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
10.12 Japan Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
11. ROW OVERACTIVE BLADDER TREATMENT MARKET: SEGMENTATION BY MEDICATION, BY THERAPY (2014-2024)
11.1 ROW Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
11.2 Market Segmentation By Medication
11.3 Market Segmentation By Therapy
12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
12.1 Global Overactive Bladder Treatment Market Drivers
12.2 Global Overactive Bladder Treatment Market Restraints
12.3 Global Overactive Bladder Treatment Market Trends
13. MARKET ATTRACTIVENESS AND STRATEGIC ANALYSIS
13.1 Market Attractiveness
13.2 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year 2024)
13.3 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
13.4 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)
14. PIPELINE PRODUCT ANALYSIS
14.1 New Technologies in Overactive Bladder Treatments
14.2 Key Pipeline Drugs in Overactive Bladder Treatment Market
14.3 Key new operative therapies in Overactive Bladder Treatment Market
15. COMPETITIVE LANDSCAPE
15.1 Market Share Analysis
15.2 SWOT Analysis
15.3 Porter’s Five Force Analysis
16. COMPANY PROFILES (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
16.1 Astellas Pharma Inc.
16.2 Allergan
16.3 Pfizer Inc.
16.4 Laborie
16.5 Teva Pharmaceutical
16.6 Intas Pharmaceutical Ltd.
16.7 Axonics Modulation Technologies, Inc.
16.8 Apotex
16.9 Macleods Pharmaceuticals Ltd.
16.10 Sanofi S.A.
LIST OF FIGURES
Figure 1: Treatment for OAB ( Without identifiable underlying causes: Idiopathic OAB)
Figure 2: Treatment for OAB ( With identifiable underlying causes)
Figure 3: Global Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 4: Share of People Aged 65+, 2015 and 2050F (In %)
Figure 5: Prevalence of Urinary Incontinence worldwide (2018)
Figure 6: Global estimates of individual with UI Grouped by year and region (In Millions)
Figure 7: Estimated Number of Male with UI by year (Million)
Figure 8: Estimated Number of Female with UI by year (Million)
Figure 9: Estimated worldwide number of individuals with OAB Syndrome by year , by sex (In Million)
Figure 10: Estimated total population number with OAB Syndrome by year (In Million)
Figure 11: Estimated numbers of individuals in major world regions Affected by OAB (In Millions)
Figure 12: Projected Global population (In Billions)
Figure 13: Projected Global population aged 60 years & above (In Billions)
Figure 14: OAB Prevalence, 2016
Figure 15: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 17: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Figure 18: Global Expected Healthcare Industry Outlook
Figure 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 21: Global Overactive Bladder Treatment Market- By Oxybutynin, By Value (USD Million), 2014-2024
Figure 22: Global Overactive Bladder Treatment Market- By Tolterodine, By Value (USD Million), 2014-2024
Figure 23: Global Overactive Bladder Treatment Market- By Trospium, By Value (USD Million), 2014-2024
Figure 24: Global Overactive Bladder Treatment Market- By Solifenacin, By Value (USD Million), 2014-2024
Figure 25: Global Overactive Bladder Treatment Market- By Mirabegron, By Value (USD Million), 2014-2024
Figure 26: Global Overactive Bladder Treatment Market- By Others, By Value (USD Million), 2014-2024
Figure 27: Global Overactive Bladder Treatment – By Therapy: 2018 & 2024
Figure 28: Global Overactive Bladder Treatment Market- By BOTOX Therapy, By Value (USD Million), 2014-2024
Figure 29: Global Overactive Bladder Market- By SNM Therapy, By Value (USD Million), 2014-2024
Figure 30: Global Overactive Bladder Treatment Market- By PTNS, By Value (USD Million), 2014-2024
Figure 31: Competitive Scenario of Global Overactive Bladder Treatment– By Region
Figure 32: North America overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 33: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 34: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
Figure 35: North America GDP, 2012-2018 (USD Trillion)
Figure 36: North America GDP per capita, current prices, 2013-2023F (In USD)
Figure 37: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 38: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 39: North America Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 40: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 41: Competitive Scenario of North America Overactive Bladder treatment market – By Country
Figure 42: United States overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 43: Unites States, Chronic Diseases Outlook, 2018
Figure 44: U.S., Population ages 65 and above, 2014-2018 (% of total)
Figure 45: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 46: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Figure 47: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 48: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 49: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 50: United States Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 51: Canada Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 52: Canada, Population ages 65 and above, 2012-2018 (% of total)
Figure 53: Canada, Population Ageing Key Facts
Figure 54: Overweight and Obese Population in Canada, 2015-2017 (% of total)
Figure 55: Canada, Population Projections (In Millions)
Figure 56: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Figure 57: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 58: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 59: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 60: Canada Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 61: Mexico Overactive Bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 62: Mexico overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 63: Mexico Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 64: Mexico Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 65: Europe overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 66: EU-5 Socio-Economical Statistics, 2018
Figure 67: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Figure 68: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Figure 69: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Figure 70: European Country Population Aged 65 and Above, 2012-2018 (% of Total)
Figure 71: GDP, Europe Region, By Select Country, 2012-2018 (In Trillion USD)
Figure 72: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 73: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 74: Europe Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 75: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 76: Europe Overactive Bladder Treatment Market – By Country: 2018 & 2024
Figure 77: France overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 78: France, Health Infrastructure, 2017
Figure 79: France, Healthcare Infrastructure Related Statistics
Figure 80: France, Sending on healthcare, 2015 & 2040
Figure 81: France, Population Ages 65 and Above (% of total), 2013-2018
Figure 82: France, Number of Hospital Beds, 2013-2017
Figure 83: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 84: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 85: France Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 86: Germany overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 87: Germany overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 88: Germany, Cause of Deaths, Percentage Change, 2007-2017
Figure 89: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Figure 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 91: Germany, Healthcare Related Statistics, 2017
Figure 92: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 93: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 94: Germany Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 95: Italy overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 96: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 97: Italy, Cause of Death, Percentage Change Between 2007-2017
Figure 98: Italy, Health Expenditure, (% of GDP), 2014-2018 (USD)
Figure 99: Italy, Population Ages 65 and Above (% of total), 2012-2018
Figure 100: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 101: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 102: Italy Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 103: Spain Overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 104: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 105: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 106: Spain Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 107: APAC overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 108: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 109: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 110: Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
Figure 111: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Figure 112: Key Healthcare industry issues to be addressed
Figure 113: Obesity Rate, By Select Country, 2017 (In Percentage)
Figure 114: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 115: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 116: APAC Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 117: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 118: APAC Overactive Bladder Treatment Market – By Country: 2018 & 2024
Figure 119: India overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 120: India, Physicians per 1000 Population, 2013-2017
Figure 121: India, Hospital Beds per 1000 Population, 2013-2017
Figure 122: India, Diseases Outlook
Figure 123: India, Medical Industry Outlook
Figure 124: India, Total Population, 2013-2023F (In Billion)
Figure 125: India, Share of Urban Population, 2012-2018 (In %)
Figure 126: India, Medical Tourism Market, 2016-2017, (USD Billion)
Figure 127: India, Population ages 65 and above, 2013-2017
Figure 128: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 129: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 130: India Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 131: China overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 132: China, Healthcare Outlook
Figure 133: China, Cause of Death, Percentage Change Between 2007-2017
Figure 134: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 135: China, Share of Urban Population, 2012-2018 (In %)
Figure 136: China, Total Population, 2013-2021F (In Billion)
Figure 137: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 138: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 139: China Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 140: Japan overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 141: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 142: Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 143: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 144: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 145: Japan Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 146: ROW overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 147: Population ages 65 and above, By Select Country, 2018 (% of total)
Figure 148: Population ages 60 or above, By Select Country, 2050 (% of total)
Figure 149: Latin America and Caribbean, Population ages 65 and above 2012-2018 (% of total)
Figure 150: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2018
Figure 151: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 152: Middle East and North Africa, GDP, 2012-2018 (In USD Trillion)
Figure 153: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 154: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 155: ROW Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 156: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year-2024)
Figure 157: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
Figure 158: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year2024
Figure 159: Astellas Pharma Inc. Sales (USD Billion), Year 2014-2018
Figure 160: Astellas Pharma Inc. Net Profit/Loss (USD Billion), Year 2014-2018
Figure 161: Astellas Pharma Inc. Sales by Geographical area (In Percentage), Year 2018
Figure 162: Astellas Pharma Inc. Sales of main products (USD Billion), Year 2018
Figure 163: Allergan , Net Sales, 2014-2018 (USD Million)
Figure 164: Allergan , By Segments, 2018 (%)
Figure 165: Allergan , By Segment, 2017 (%)
Figure 166: Pfizer Inc. Total Revenue (USD Billion), Year 2014-2018
Figure 167: Pfizer Inc. Net Income (USD Million), Year 2014-2018
Figure 168: Pfizer Inc. Revenue by National Market (In percentage)
Figure 169: Pfizer Inc. Segment Revenue (USD Billion)
Figure 170: Teva Pharmaceuticals Net Revenue (USD Billion), Year 2014-2018
Figure 171: Teva Pharmaceuticals Net Income (USD Billion), Year 2014-2018
Figure 172: Teva Pharmaceuticals Revenue By geographical area (USD Million)
Figure 173: Teva Pharmaceuticals Major product Revenue in North America (USD Million)
Figure 174: Intas Pharmaceuticals Ltd. Sales Revenue (USD Million), Year 2015-2019
Figure 175: Intas Pharmaceuticals Ltd. Net Income (USD Million), Year 2015-2019
Figure 176: Intas Pharmaceuticals Ltd. Revenue by National Market (In percentage)
Figure 177: Axonics Net Revenue (USD Thousands), Year 2018-2017
Figure 178: Sanofi S.A. Total Revenue (USD Billion), Year 2014-2018
Figure 179: Sanofi S.A. Net Income (USD Million), Year 2014-2018
Figure 180: Sanofi S.A, Revenue by Global Business Unit (USD Billion)
Figure 181: Sanofi S.A. By operating segment (USD Billion)
Figure 1: Treatment for OAB ( Without identifiable underlying causes: Idiopathic OAB)
Figure 2: Treatment for OAB ( With identifiable underlying causes)
Figure 3: Global Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 4: Share of People Aged 65+, 2015 and 2050F (In %)
Figure 5: Prevalence of Urinary Incontinence worldwide (2018)
Figure 6: Global estimates of individual with UI Grouped by year and region (In Millions)
Figure 7: Estimated Number of Male with UI by year (Million)
Figure 8: Estimated Number of Female with UI by year (Million)
Figure 9: Estimated worldwide number of individuals with OAB Syndrome by year , by sex (In Million)
Figure 10: Estimated total population number with OAB Syndrome by year (In Million)
Figure 11: Estimated numbers of individuals in major world regions Affected by OAB (In Millions)
Figure 12: Projected Global population (In Billions)
Figure 13: Projected Global population aged 60 years & above (In Billions)
Figure 14: OAB Prevalence, 2016
Figure 15: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 17: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Figure 18: Global Expected Healthcare Industry Outlook
Figure 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 21: Global Overactive Bladder Treatment Market- By Oxybutynin, By Value (USD Million), 2014-2024
Figure 22: Global Overactive Bladder Treatment Market- By Tolterodine, By Value (USD Million), 2014-2024
Figure 23: Global Overactive Bladder Treatment Market- By Trospium, By Value (USD Million), 2014-2024
Figure 24: Global Overactive Bladder Treatment Market- By Solifenacin, By Value (USD Million), 2014-2024
Figure 25: Global Overactive Bladder Treatment Market- By Mirabegron, By Value (USD Million), 2014-2024
Figure 26: Global Overactive Bladder Treatment Market- By Others, By Value (USD Million), 2014-2024
Figure 27: Global Overactive Bladder Treatment – By Therapy: 2018 & 2024
Figure 28: Global Overactive Bladder Treatment Market- By BOTOX Therapy, By Value (USD Million), 2014-2024
Figure 29: Global Overactive Bladder Market- By SNM Therapy, By Value (USD Million), 2014-2024
Figure 30: Global Overactive Bladder Treatment Market- By PTNS, By Value (USD Million), 2014-2024
Figure 31: Competitive Scenario of Global Overactive Bladder Treatment– By Region
Figure 32: North America overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 33: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 34: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
Figure 35: North America GDP, 2012-2018 (USD Trillion)
Figure 36: North America GDP per capita, current prices, 2013-2023F (In USD)
Figure 37: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 38: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 39: North America Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 40: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 41: Competitive Scenario of North America Overactive Bladder treatment market – By Country
Figure 42: United States overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 43: Unites States, Chronic Diseases Outlook, 2018
Figure 44: U.S., Population ages 65 and above, 2014-2018 (% of total)
Figure 45: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 46: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Figure 47: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 48: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 49: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 50: United States Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 51: Canada Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 52: Canada, Population ages 65 and above, 2012-2018 (% of total)
Figure 53: Canada, Population Ageing Key Facts
Figure 54: Overweight and Obese Population in Canada, 2015-2017 (% of total)
Figure 55: Canada, Population Projections (In Millions)
Figure 56: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Figure 57: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 58: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 59: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 60: Canada Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 61: Mexico Overactive Bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 62: Mexico overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 63: Mexico Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 64: Mexico Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 65: Europe overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 66: EU-5 Socio-Economical Statistics, 2018
Figure 67: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Figure 68: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Figure 69: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Figure 70: European Country Population Aged 65 and Above, 2012-2018 (% of Total)
Figure 71: GDP, Europe Region, By Select Country, 2012-2018 (In Trillion USD)
Figure 72: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 73: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 74: Europe Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 75: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 76: Europe Overactive Bladder Treatment Market – By Country: 2018 & 2024
Figure 77: France overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 78: France, Health Infrastructure, 2017
Figure 79: France, Healthcare Infrastructure Related Statistics
Figure 80: France, Sending on healthcare, 2015 & 2040
Figure 81: France, Population Ages 65 and Above (% of total), 2013-2018
Figure 82: France, Number of Hospital Beds, 2013-2017
Figure 83: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 84: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 85: France Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 86: Germany overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 87: Germany overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 88: Germany, Cause of Deaths, Percentage Change, 2007-2017
Figure 89: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Figure 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 91: Germany, Healthcare Related Statistics, 2017
Figure 92: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 93: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 94: Germany Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 95: Italy overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 96: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 97: Italy, Cause of Death, Percentage Change Between 2007-2017
Figure 98: Italy, Health Expenditure, (% of GDP), 2014-2018 (USD)
Figure 99: Italy, Population Ages 65 and Above (% of total), 2012-2018
Figure 100: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 101: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 102: Italy Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 103: Spain Overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 104: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 105: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 106: Spain Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 107: APAC overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 108: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 109: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 110: Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
Figure 111: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Figure 112: Key Healthcare industry issues to be addressed
Figure 113: Obesity Rate, By Select Country, 2017 (In Percentage)
Figure 114: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 115: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 116: APAC Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 117: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
Figure 118: APAC Overactive Bladder Treatment Market – By Country: 2018 & 2024
Figure 119: India overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 120: India, Physicians per 1000 Population, 2013-2017
Figure 121: India, Hospital Beds per 1000 Population, 2013-2017
Figure 122: India, Diseases Outlook
Figure 123: India, Medical Industry Outlook
Figure 124: India, Total Population, 2013-2023F (In Billion)
Figure 125: India, Share of Urban Population, 2012-2018 (In %)
Figure 126: India, Medical Tourism Market, 2016-2017, (USD Billion)
Figure 127: India, Population ages 65 and above, 2013-2017
Figure 128: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 129: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 130: India Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 131: China overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 132: China, Healthcare Outlook
Figure 133: China, Cause of Death, Percentage Change Between 2007-2017
Figure 134: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 135: China, Share of Urban Population, 2012-2018 (In %)
Figure 136: China, Total Population, 2013-2021F (In Billion)
Figure 137: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 138: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 139: China Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 140: Japan overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 141: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 142: Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 143: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 144: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 145: Japan Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 146: ROW overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Figure 147: Population ages 65 and above, By Select Country, 2018 (% of total)
Figure 148: Population ages 60 or above, By Select Country, 2050 (% of total)
Figure 149: Latin America and Caribbean, Population ages 65 and above 2012-2018 (% of total)
Figure 150: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2018
Figure 151: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 152: Middle East and North Africa, GDP, 2012-2018 (In USD Trillion)
Figure 153: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 154: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Figure 155: ROW Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
Figure 156: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year-2024)
Figure 157: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
Figure 158: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year2024
Figure 159: Astellas Pharma Inc. Sales (USD Billion), Year 2014-2018
Figure 160: Astellas Pharma Inc. Net Profit/Loss (USD Billion), Year 2014-2018
Figure 161: Astellas Pharma Inc. Sales by Geographical area (In Percentage), Year 2018
Figure 162: Astellas Pharma Inc. Sales of main products (USD Billion), Year 2018
Figure 163: Allergan , Net Sales, 2014-2018 (USD Million)
Figure 164: Allergan , By Segments, 2018 (%)
Figure 165: Allergan , By Segment, 2017 (%)
Figure 166: Pfizer Inc. Total Revenue (USD Billion), Year 2014-2018
Figure 167: Pfizer Inc. Net Income (USD Million), Year 2014-2018
Figure 168: Pfizer Inc. Revenue by National Market (In percentage)
Figure 169: Pfizer Inc. Segment Revenue (USD Billion)
Figure 170: Teva Pharmaceuticals Net Revenue (USD Billion), Year 2014-2018
Figure 171: Teva Pharmaceuticals Net Income (USD Billion), Year 2014-2018
Figure 172: Teva Pharmaceuticals Revenue By geographical area (USD Million)
Figure 173: Teva Pharmaceuticals Major product Revenue in North America (USD Million)
Figure 174: Intas Pharmaceuticals Ltd. Sales Revenue (USD Million), Year 2015-2019
Figure 175: Intas Pharmaceuticals Ltd. Net Income (USD Million), Year 2015-2019
Figure 176: Intas Pharmaceuticals Ltd. Revenue by National Market (In percentage)
Figure 177: Axonics Net Revenue (USD Thousands), Year 2018-2017
Figure 178: Sanofi S.A. Total Revenue (USD Billion), Year 2014-2018
Figure 179: Sanofi S.A. Net Income (USD Million), Year 2014-2018
Figure 180: Sanofi S.A, Revenue by Global Business Unit (USD Billion)
Figure 181: Sanofi S.A. By operating segment (USD Billion)
LIST OF TABLES
Table A: Unites States, Hospitals Related Statistics, In 2018
Table B: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table C: Healthcare expenditure pattern in Middle East and North Africa, In 2017
Table D: Pharmaceutical expenditure in relation to healthcare expenditure in Middle East and North Africa, In 2017
Table E: Urovant pipeline products for OAB Treatment
Table F: Allergan pipeline products for OAB Treatment
Table G: Astellas pipeline products for OAB Treatment
Table A: Unites States, Hospitals Related Statistics, In 2018
Table B: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table C: Healthcare expenditure pattern in Middle East and North Africa, In 2017
Table D: Pharmaceutical expenditure in relation to healthcare expenditure in Middle East and North Africa, In 2017
Table E: Urovant pipeline products for OAB Treatment
Table F: Allergan pipeline products for OAB Treatment
Table G: Astellas pipeline products for OAB Treatment
